Sanofi-Aventis - Search News

Sanofi, tolebrutinib

Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Reuters on MSN · 1d

New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection

Benzinga.com · 1d

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,

GlobalData on MSN · 1d

Sanofi’s eyes approval after MS therapy slows disease progression by 31%

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.

Reuters on MSN · 1d

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.

Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

FierceBiotech1d

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

The Pharma Letter4d

Sanofi shipping RSV jab Beyfortus in USA

French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...

Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

7don MSN

Makers of sodium valproate sent 'clear message' after Sanofi ordered to pay €280,000 to mother whose children were harmed

Marketed since 1967 it has been found the drug "can cause problems for a baby's development, including birth defects and ...

Dispute with Sanofi settled, Panacea scrip soars to over 3-yr high

Panacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High ...

BioPharma Dive1d

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

10d

Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...

FiercePharma4d

With amped up manufacturing effort, Sanofi and AZ look to avoid Beyfortus shortfalls this year

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results